Paper Details

  1. Home
  2. Paper Details

Real-Life Experience of the Effects of Cladribine Tablets on Lymphocyte Subsets and Serum Neurofilament Light Chain Levels in Relapsing Multiple Sclerosis Patients.

Author: BolloLuca, CarleoGraziana, FrigeriAntonio, GarganoConcetta D, GuerraTommaso, IaffaldanoAntonio, IaffaldanoPietro, ManniAlessia, PalazzoClaudia, PaolicelliDamiano, RuggieriMaddalena, SaracinoAnnalisa, TrojanoMaria

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study assessed the effects of cladribine, an immunosuppressive drug, on different lymphocyte subsets and serum neurofilament light chain (sNfL) levels in patients with relapsing multiple sclerosis (MS). Cladribine induced significant reductions in B cell subsets, with a transient increase in T regulatory cells. Although these changes were not predictive of no evidence of disease activity (NEDA) achievement, sNfL levels were significantly lower at week 24, suggesting that cladribine may reduce axonal damage.
Paper Details　
Original Abstract of the Article :
Although cladribine induces sustained reductions in peripheral T and B lymphocytes, little is known about its effect on axonal damage reduction in multiple sclerosis (MS), which could be demonstrated by assessing the serum neurofilament light chain (sNfL) levels. We investigated the reduction/recons...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9776379/

データ提供：米国国立医学図書館（NLM）

Cladribine: A Promising Treatment for Relapsing Multiple Sclerosis

The field of multiple sclerosis (MS) research is constantly seeking new and effective treatments to manage this complex and debilitating neurological condition. This study investigates the effects of cladribine, a drug used to treat relapsing MS, on lymphocyte subsets and serum neurofilament light chain (sNfL) levels. The study found that cladribine effectively reduced lymphocyte subsets, suggesting its potential to modulate immune activity and reduce axonal damage. These findings offer a promising avenue for treating relapsing MS and improving the quality of life for individuals living with this condition.

Cladribine: A Promising Treatment for Relapsing Multiple Sclerosis

The study's findings demonstrate the effectiveness of cladribine in reducing lymphocyte subsets, suggesting its potential to modulate immune activity and reduce axonal damage. The reduction in sNfL levels further supports the potential of cladribine in mitigating axonal damage in relapsing MS.

Navigating the Complexities of Multiple Sclerosis Treatment

The complex nature of MS requires a multifaceted approach to treatment. This study highlights the potential of cladribine as a treatment option for relapsing MS. However, it's important to note that further research is needed to fully understand the long-term effects of cladribine and to develop personalized treatment plans based on individual needs. As always, consulting with a healthcare professional is crucial for personalized diagnosis and treatment plans.

Dr. Camel's Conclusion

Just as a camel navigates the ever-changing desert landscape, individuals with MS face a challenging journey. This study offers a promising glimpse into the potential of cladribine as a treatment option for relapsing MS, providing a beacon of hope for those seeking relief from this debilitating condition. While further research is ongoing, the findings present a valuable step towards a future where MS can be effectively managed and quality of life can be improved.

Date :
  1. Date Completed n.d.
  2. Date Revised 2022-12-25
Further Info :

Pubmed ID

36552055

DOI: Digital Object Identifier

PMC9776379

Related Literature

Article Analysis
・Effects of cladribine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.